Compare Canadian Pacific Kansas City Limited Common Shares (CP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian Pacific Kansas City Limited Common Shares vs Incyte Corporation — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $84.24 (market cap $73.98B), while Incyte Corporation trades at $113.19 (market cap $22.85B). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 3.2× Incyte Corporation's market cap, and Canadian Pacific Kansas City Limited Common Shares pays a 0.9% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CP | INCY | |
|---|---|---|
Market Cap | $73.98B | $22.85B |
Volume | 1,669,828 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $96.69 | $129.93 |
52-Week Low | $68.88 | $83.80 |
Enterprise Value | $91.36B | $18.35B |
Dividend Yield | 0.9% | — |
Typical Hold Time | — | 33 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canadian Pacific Kansas City Limited Common Shares
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
